ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 000215

Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease

Identifieur interne : 000215 ( PascalFrancis/Corpus ); précédent : 000214; suivant : 000216

Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease

Auteurs : Stephanie Bannier ; Jean Louis Berdague ; Isabelle Rieu ; Ingrid De Chazeron ; Ana Marques ; Philippe Derost ; Miguel Ulla ; Pierre-Michel Llorca ; Franck Durif

Source :

Journal of neurology, neurosurgery and psychiatry [ 0022-3050 ] ; 2012.

RBID : Pascal:12-0384347

Descripteurs français

Pascal (Inist)
- Hallucination, Maladie de Parkinson, Pathologie du système nerveux, Prévalence.

English descriptors

KwdEn :
- Hallucination, Nervous system diseases, Parkinson disease, Prevalence.

Abstract

Background Although visual hallucinations in Parkinson's disease (PD) have been described in several major studies, little is known about olfactory hallucinations (0Hs). Methods The authors performed a detailed analysis of OHs in a cohort of 87 Parkinsonian patients to estimate the prevalence of OHs and describe their phenomenology. They also evaluated smelling abilities in terms of detection and identification. Assessment of both, OHs and olfactory function, was also performed using a control group of 40 normal subjects. Results Nine patients exhibited OHs compared with none of the controls, giving a prevalence of 10% for OHs in patients. OHs were described as rare, short-lasting, unpleasant odours which are not frightening since clearly identified by the patient as hallucinations. Parkinsonian patients with OHs exhibited olfactory impairment of detection and identification compared with controls, but there was no difference in their olfactory abilities from Parkinsonian patients without OHs. Conclusions In conclusion, OHs should be added to the list of non-motor PD symptoms that can occur early or late in the course of PD. The authors' study did not reveal any significant difference in terms of olfactory abilities between patients with or without OHs. However, olfactory impairment is well documented in Parkinsonian patients and cannot be totally ruled out as a risk factor for OHs. The authors recognise that complex mechanisms are probably involved in this phenomenon.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-3050`
A02	`01`			`@0 JNNPAU`
A03		`1`		`@0 J. neurol. neurosurg. psychiatry`
A05				`@2 83`
A06				`@2 10`
A08	`01`	`1`	`ENG`	`@1 Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease`
A11	`01`	`1`		`@1 BANNIER (Stephanie)`
A11	`02`	`1`		`@1 BERDAGUE (Jean Louis)`
A11	`03`	`1`		`@1 RIEU (Isabelle)`
A11	`04`	`1`		`@1 DE CHAZERON (Ingrid)`
A11	`05`	`1`		`@1 MARQUES (Ana)`
A11	`06`	`1`		`@1 DEROST (Philippe)`
A11	`07`	`1`		`@1 ULLA (Miguel)`
A11	`08`	`1`		`@1 LLORCA (Pierre-Michel)`
A11	`09`	`1`		`@1 DURIF (Franck)`
A14	`01`			`@1 CHU Clermont-Ferrand, Neurology Department @2 Clermont-Ferrand @3 FRA @Z 1 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 9 aut.`
A14	`02`			`@1 Univ Clermont 1, UFR Medecine @2 Clermont-Ferrand @3 FRA @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut.`
A14	`03`			`@1 INRA, UR454 Microbiologie @2 Saint-Genès Champanelle @3 FRA @Z 2 aut.`
A14	`04`			`@1 CHU Clermont-Ferrand, Department of Psychiatry B @2 Clermont-Ferrand @3 FRA @Z 4 aut. @Z 8 aut.`
A20				`@1 1019-1021`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6015 @5 354000502029290180`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 15 ref.`
A47	`01`	`1`		`@0 12-0384347`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of neurology, neurosurgery and psychiatry`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background Although visual hallucinations in Parkinson's disease (PD) have been described in several major studies, little is known about olfactory hallucinations (0Hs). Methods The authors performed a detailed analysis of OHs in a cohort of 87 Parkinsonian patients to estimate the prevalence of OHs and describe their phenomenology. They also evaluated smelling abilities in terms of detection and identification. Assessment of both, OHs and olfactory function, was also performed using a control group of 40 normal subjects. Results Nine patients exhibited OHs compared with none of the controls, giving a prevalence of 10% for OHs in patients. OHs were described as rare, short-lasting, unpleasant odours which are not frightening since clearly identified by the patient as hallucinations. Parkinsonian patients with OHs exhibited olfactory impairment of detection and identification compared with controls, but there was no difference in their olfactory abilities from Parkinsonian patients without OHs. Conclusions In conclusion, OHs should be added to the list of non-motor PD symptoms that can occur early or late in the course of PD. The authors' study did not reveal any significant difference in terms of olfactory abilities between patients with or without OHs. However, olfactory impairment is well documented in Parkinsonian patients and cannot be totally ruled out as a risk factor for OHs. The authors recognise that complex mechanisms are probably involved in this phenomenon.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Hallucination @5 01`
C03	`01`	`X`	`ENG`	`@0 Hallucination @5 01`
C03	`01`	`X`	`SPA`	`@0 Alucinación @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Prévalence @5 09`
C03	`04`	`X`	`ENG`	`@0 Prevalence @5 09`
C03	`04`	`X`	`SPA`	`@0 Prevalencia @5 09`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 296`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0384347 INIST
ET :	Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease
AU :	BANNIER (Stephanie); BERDAGUE (Jean Louis); RIEU (Isabelle); DE CHAZERON (Ingrid); MARQUES (Ana); DEROST (Philippe); ULLA (Miguel); LLORCA (Pierre-Michel); DURIF (Franck)
AF :	CHU Clermont-Ferrand, Neurology Department/Clermont-Ferrand/France (1 aut., 3 aut., 5 aut., 6 aut., 7 aut., 9 aut.); Univ Clermont 1, UFR Medecine/Clermont-Ferrand/France (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut.); INRA, UR454 Microbiologie/Saint-Genès Champanelle/France (2 aut.); CHU Clermont-Ferrand, Department of Psychiatry B/Clermont-Ferrand/France (4 aut., 8 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Journal of neurology, neurosurgery and psychiatry; ISSN 0022-3050; Coden JNNPAU; Royaume-Uni; Da. 2012; Vol. 83; No. 10; Pp. 1019-1021; Bibl. 15 ref.
LA :	Anglais
EA :	Background Although visual hallucinations in Parkinson's disease (PD) have been described in several major studies, little is known about olfactory hallucinations (0Hs). Methods The authors performed a detailed analysis of OHs in a cohort of 87 Parkinsonian patients to estimate the prevalence of OHs and describe their phenomenology. They also evaluated smelling abilities in terms of detection and identification. Assessment of both, OHs and olfactory function, was also performed using a control group of 40 normal subjects. Results Nine patients exhibited OHs compared with none of the controls, giving a prevalence of 10% for OHs in patients. OHs were described as rare, short-lasting, unpleasant odours which are not frightening since clearly identified by the patient as hallucinations. Parkinsonian patients with OHs exhibited olfactory impairment of detection and identification compared with controls, but there was no difference in their olfactory abilities from Parkinsonian patients without OHs. Conclusions In conclusion, OHs should be added to the list of non-motor PD symptoms that can occur early or late in the course of PD. The authors' study did not reveal any significant difference in terms of olfactory abilities between patients with or without OHs. However, olfactory impairment is well documented in Parkinsonian patients and cannot be totally ruled out as a risk factor for OHs. The authors recognise that complex mechanisms are probably involved in this phenomenon.
CC :	002B17; 002B17G
FD :	Hallucination; Maladie de Parkinson; Pathologie du système nerveux; Prévalence
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Hallucination; Parkinson disease; Nervous system diseases; Prevalence
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Alucinación; Parkinson enfermedad; Sistema nervioso patología; Prevalencia
LO :	INIST-6015.354000502029290180
ID :	12-0384347

Links to Exploration step

Pascal:12-0384347

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease</title>
<author><name sortKey="Bannier, Stephanie" sort="Bannier, Stephanie" uniqKey="Bannier S" first="Stephanie" last="Bannier">Stephanie Bannier</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berdague, Jean Louis" sort="Berdague, Jean Louis" uniqKey="Berdague J" first="Jean Louis" last="Berdague">Jean Louis Berdague</name>
<affiliation><inist:fA14 i1="03"><s1>INRA, UR454 Microbiologie</s1>
<s2>Saint-Genès Champanelle</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rieu, Isabelle" sort="Rieu, Isabelle" uniqKey="Rieu I" first="Isabelle" last="Rieu">Isabelle Rieu</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Chazeron, Ingrid" sort="De Chazeron, Ingrid" uniqKey="De Chazeron I" first="Ingrid" last="De Chazeron">Ingrid De Chazeron</name>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>CHU Clermont-Ferrand, Department of Psychiatry B</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marques, Ana" sort="Marques, Ana" uniqKey="Marques A" first="Ana" last="Marques">Ana Marques</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Derost, Philippe" sort="Derost, Philippe" uniqKey="Derost P" first="Philippe" last="Derost">Philippe Derost</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ulla, Miguel" sort="Ulla, Miguel" uniqKey="Ulla M" first="Miguel" last="Ulla">Miguel Ulla</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Llorca, Pierre Michel" sort="Llorca, Pierre Michel" uniqKey="Llorca P" first="Pierre-Michel" last="Llorca">Pierre-Michel Llorca</name>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>CHU Clermont-Ferrand, Department of Psychiatry B</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0384347</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0384347 INIST</idno>
<idno type="RBID">Pascal:12-0384347</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000215</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease</title>
<author><name sortKey="Bannier, Stephanie" sort="Bannier, Stephanie" uniqKey="Bannier S" first="Stephanie" last="Bannier">Stephanie Bannier</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berdague, Jean Louis" sort="Berdague, Jean Louis" uniqKey="Berdague J" first="Jean Louis" last="Berdague">Jean Louis Berdague</name>
<affiliation><inist:fA14 i1="03"><s1>INRA, UR454 Microbiologie</s1>
<s2>Saint-Genès Champanelle</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rieu, Isabelle" sort="Rieu, Isabelle" uniqKey="Rieu I" first="Isabelle" last="Rieu">Isabelle Rieu</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Chazeron, Ingrid" sort="De Chazeron, Ingrid" uniqKey="De Chazeron I" first="Ingrid" last="De Chazeron">Ingrid De Chazeron</name>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>CHU Clermont-Ferrand, Department of Psychiatry B</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marques, Ana" sort="Marques, Ana" uniqKey="Marques A" first="Ana" last="Marques">Ana Marques</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Derost, Philippe" sort="Derost, Philippe" uniqKey="Derost P" first="Philippe" last="Derost">Philippe Derost</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ulla, Miguel" sort="Ulla, Miguel" uniqKey="Ulla M" first="Miguel" last="Ulla">Miguel Ulla</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Llorca, Pierre Michel" sort="Llorca, Pierre Michel" uniqKey="Llorca P" first="Pierre-Michel" last="Llorca">Pierre-Michel Llorca</name>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>CHU Clermont-Ferrand, Department of Psychiatry B</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name>
<affiliation><inist:fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of neurology, neurosurgery and psychiatry</title>
<title level="j" type="abbreviated">J. neurol. neurosurg. psychiatry</title>
<idno type="ISSN">0022-3050</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of neurology, neurosurgery and psychiatry</title>
<title level="j" type="abbreviated">J. neurol. neurosurg. psychiatry</title>
<idno type="ISSN">0022-3050</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Hallucination</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Prevalence</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Hallucination</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Prévalence</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background Although visual hallucinations in Parkinson's disease (PD) have been described in several major studies, little is known about olfactory hallucinations (0Hs). Methods The authors performed a detailed analysis of OHs in a cohort of 87 Parkinsonian patients to estimate the prevalence of OHs and describe their phenomenology. They also evaluated smelling abilities in terms of detection and identification. Assessment of both, OHs and olfactory function, was also performed using a control group of 40 normal subjects. Results Nine patients exhibited OHs compared with none of the controls, giving a prevalence of 10% for OHs in patients. OHs were described as rare, short-lasting, unpleasant odours which are not frightening since clearly identified by the patient as hallucinations. Parkinsonian patients with OHs exhibited olfactory impairment of detection and identification compared with controls, but there was no difference in their olfactory abilities from Parkinsonian patients without OHs. Conclusions In conclusion, OHs should be added to the list of non-motor PD symptoms that can occur early or late in the course of PD. The authors' study did not reveal any significant difference in terms of olfactory abilities between patients with or without OHs. However, olfactory impairment is well documented in Parkinsonian patients and cannot be totally ruled out as a risk factor for OHs. The authors recognise that complex mechanisms are probably involved in this phenomenon.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-3050</s0>
</fA01>
<fA02 i1="01"><s0>JNNPAU</s0>
</fA02>
<fA03 i2="1"><s0>J. neurol. neurosurg. psychiatry</s0>
</fA03>
<fA05><s2>83</s2>
</fA05>
<fA06><s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BANNIER (Stephanie)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BERDAGUE (Jean Louis)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>RIEU (Isabelle)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DE CHAZERON (Ingrid)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MARQUES (Ana)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>DEROST (Philippe)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ULLA (Miguel)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>LLORCA (Pierre-Michel)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>DURIF (Franck)</s1>
</fA11>
<fA14 i1="01"><s1>CHU Clermont-Ferrand, Neurology Department</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Univ Clermont 1, UFR Medecine</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>INRA, UR454 Microbiologie</s1>
<s2>Saint-Genès Champanelle</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>CHU Clermont-Ferrand, Department of Psychiatry B</s1>
<s2>Clermont-Ferrand</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>1019-1021</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6015</s2>
<s5>354000502029290180</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>15 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0384347</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of neurology, neurosurgery and psychiatry</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background Although visual hallucinations in Parkinson's disease (PD) have been described in several major studies, little is known about olfactory hallucinations (0Hs). Methods The authors performed a detailed analysis of OHs in a cohort of 87 Parkinsonian patients to estimate the prevalence of OHs and describe their phenomenology. They also evaluated smelling abilities in terms of detection and identification. Assessment of both, OHs and olfactory function, was also performed using a control group of 40 normal subjects. Results Nine patients exhibited OHs compared with none of the controls, giving a prevalence of 10% for OHs in patients. OHs were described as rare, short-lasting, unpleasant odours which are not frightening since clearly identified by the patient as hallucinations. Parkinsonian patients with OHs exhibited olfactory impairment of detection and identification compared with controls, but there was no difference in their olfactory abilities from Parkinsonian patients without OHs. Conclusions In conclusion, OHs should be added to the list of non-motor PD symptoms that can occur early or late in the course of PD. The authors' study did not reveal any significant difference in terms of olfactory abilities between patients with or without OHs. However, olfactory impairment is well documented in Parkinsonian patients and cannot be totally ruled out as a risk factor for OHs. The authors recognise that complex mechanisms are probably involved in this phenomenon.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Hallucination</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Hallucination</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Alucinación</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>296</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0384347 INIST</NO>
<ET>Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease</ET>
<AU>BANNIER (Stephanie); BERDAGUE (Jean Louis); RIEU (Isabelle); DE CHAZERON (Ingrid); MARQUES (Ana); DEROST (Philippe); ULLA (Miguel); LLORCA (Pierre-Michel); DURIF (Franck)</AU>
<AF>CHU Clermont-Ferrand, Neurology Department/Clermont-Ferrand/France (1 aut., 3 aut., 5 aut., 6 aut., 7 aut., 9 aut.); Univ Clermont 1, UFR Medecine/Clermont-Ferrand/France (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut.); INRA, UR454 Microbiologie/Saint-Genès Champanelle/France (2 aut.); CHU Clermont-Ferrand, Department of Psychiatry B/Clermont-Ferrand/France (4 aut., 8 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Journal of neurology, neurosurgery and psychiatry; ISSN 0022-3050; Coden JNNPAU; Royaume-Uni; Da. 2012; Vol. 83; No. 10; Pp. 1019-1021; Bibl. 15 ref.</SO>
<LA>Anglais</LA>
<EA>Background Although visual hallucinations in Parkinson's disease (PD) have been described in several major studies, little is known about olfactory hallucinations (0Hs). Methods The authors performed a detailed analysis of OHs in a cohort of 87 Parkinsonian patients to estimate the prevalence of OHs and describe their phenomenology. They also evaluated smelling abilities in terms of detection and identification. Assessment of both, OHs and olfactory function, was also performed using a control group of 40 normal subjects. Results Nine patients exhibited OHs compared with none of the controls, giving a prevalence of 10% for OHs in patients. OHs were described as rare, short-lasting, unpleasant odours which are not frightening since clearly identified by the patient as hallucinations. Parkinsonian patients with OHs exhibited olfactory impairment of detection and identification compared with controls, but there was no difference in their olfactory abilities from Parkinsonian patients without OHs. Conclusions In conclusion, OHs should be added to the list of non-motor PD symptoms that can occur early or late in the course of PD. The authors' study did not reveal any significant difference in terms of olfactory abilities between patients with or without OHs. However, olfactory impairment is well documented in Parkinsonian patients and cannot be totally ruled out as a risk factor for OHs. The authors recognise that complex mechanisms are probably involved in this phenomenon.</EA>
<CC>002B17; 002B17G</CC>
<FD>Hallucination; Maladie de Parkinson; Pathologie du   système nerveux; Prévalence</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Hallucination; Parkinson disease; Nervous system diseases; Prevalence</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Alucinación; Parkinson enfermedad; Sistema nervioso patología; Prevalencia</SD>
<LO>INIST-6015.354000502029290180</LO>
<ID>12-0384347</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000215 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000215 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0384347
   |texte=   Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease

Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri